FLT3 and acute myeloid leukemia: Comprehensively, we tried to show the clinical data of FLT3 inhibitors for AML patients with FLT3 mutations, which were arranged and compared according to the frontline, the R/R setting, and maintenance therapy after allo-SCT in patients with FLT3-mutated AML.